DECREASED PLASMA-LEVELS OF LIPOPROTEIN(A) IN PATIENTS WITH HYPERTRIGLYCERIDEMIA

被引:42
作者
BARTENS, W [1 ]
RADER, DJ [1 ]
TALLEY, G [1 ]
BREWER, HB [1 ]
机构
[1] NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892
关键词
APOLIPOPROTEIN (A); ATHEROSCLEROSIS; CHOLESTEROL; HYPERTRIGLYCERIDEMIA;
D O I
10.1016/0021-9150(94)90109-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein(a) (Lp(a)) is an atherogenic lipoprotein which is similar in structure to, but metabolically distinct from, LDL. Factors modulating plasma Lp(a) concentrations are poorly understood. To investigate the possible interaction of Lp(a) with triglycerides, we determined the apo(a) phenotype, Lp(a) concentration, and distribution of Lp(a) in a group of patients with triglycerides > 400 mg/dl (n = 60) compared with a control group (n = 128). Lp(a) concentrations were significantly lower in hypertriglyceridemic patients (mean +/- S.E., 13 +/- 4 mg/dl; median, 6 mg/dl; 25/75 percentile, 2-13 mg/dl) as compared with the controls (mean, 22 +/- 2 mg/dl; median, 10 mg/dl; 25/75 percentile, 7-30 mg/dl). Plasma Lp(a) concentrations in the hypertriglyceridemic patients correlated negatively with triglyceride levels (r = -0.69, P = 0.03). The difference in Lp(a) levels between patients and controls was maintained when subjects were stratified by apo(a) phenotype and type of hyperlipidemia. After subdividing the hypertriglyceridemic patients into one group with apo(a) isoforms less than or equal to S2 and one group with apo(a) isoforms greater than or equal to S3, we found that the differences in plasma Lp(a) concentrations between patients and controls were more pronounced in the group with the lower molecular weight apo(a) isoforms. These data indicate that hypertriglyceridemia is associated with lower plasma Lp(a) concentrations and suggest that increased levels of triglyceride-rich lipoproteins may influence the metabolism of Lp(a).
引用
收藏
页码:149 / 157
页数:9
相关论文
共 38 条
[11]  
GAUBATZ JW, 1990, J LIPID RES, V31, P603
[12]   LACK OF CHANGE OF LIPOPROTEIN (A) CONCENTRATION WITH IMPROVED GLYCEMIC CONTROL IN SUBJECTS WITH TYPE-II DIABETES [J].
HAFFNER, SM ;
TUTTLE, KR ;
RAINWATER, DL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (02) :116-120
[13]   CATABOLISM OF LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS [J].
KNIGHT, BL ;
PEROMBELON, YFN ;
SOUTAR, AK ;
WADE, DP ;
SEED, M .
ATHEROSCLEROSIS, 1991, 87 (2-3) :227-237
[14]   CHANGES OF GENETIC APOLIPOPROTEIN PHENOTYPES CAUSED BY LIVER-TRANSPLANTATION - IMPLICATIONS FOR APOLIPOPROTEIN SYNTHESIS [J].
KRAFT, HG ;
MENZEL, HJ ;
HOPPICHLER, F ;
VOGEL, W ;
UTERMANN, G .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (01) :137-142
[15]  
KREMPLER F, 1979, BIOCHIM BIOPHYS ACTA, V575, P63, DOI 10.1016/0005-2760(79)90131-0
[16]   MOLECULAR-BASIS OF APOLIPOPROTEIN-(A) ISOFORM SIZE HETEROGENEITY AS REVEALED BY PULSED-FIELD GEL-ELECTROPHORESIS [J].
LACKNER, C ;
BOERWINKLE, E ;
LEFFERT, CC ;
RAHMIG, T ;
HOBBS, HH .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2153-2161
[17]   ATHEROGENESIS IN TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A) [J].
LAWN, RM ;
WADE, DP ;
HAMMER, RE ;
CHIESA, G ;
VERSTUYFT, JG ;
RUBIN, EM .
NATURE, 1992, 360 (6405) :670-672
[18]   CDNA SEQUENCE OF HUMAN APOLIPOPROTEIN(A) IS HOMOLOGOUS TO PLASMINOGEN [J].
MCLEAN, JW ;
TOMLINSON, JE ;
KUANG, WJ ;
EATON, DL ;
CHEN, EY ;
FLESS, GM ;
SCANU, AM ;
LAWN, RM .
NATURE, 1987, 330 (6144) :132-137
[19]  
PARRA HJ, 1987, CLIN CHEM, V33, P721
[20]  
PFAFFINGER D, 1991, J LIPID RES, V32, P679